Articles related to BIOSIMILARS

PBMs’ vertical integration allows them to dictate cancer treatment decisions, from drug selection to delivery methods, potentially compromising patient care and increasing costs.

As pharmacists, it’s crucial to note that, although these changes in FDA guidelines may not directly impact your practice, they signify a shift in how biosimilars will be identified moving forward. This could potentially influence how you advise patients about these products.

Explore the FDA-approved Tyruko, a biosimilar to Tysabri, which has shown comparable safety and efficacy in phase 3 clinical trials for treating relapsing forms of MS.

Discover how the 340B Drug Pricing Program influences prescription trends toward higher-cost biologics over biosimilars, and what this means for cost-effective healthcare.

Amid emerging safety concerns, ADC Therapeutics has paused its mid-stage trial of Zynlonta, a potential game-changer in treating certain types of blood cancer, calling into question the drug’s future trajectory.

In the US, the use of biosimilars is becoming more and more important because of the potential for cost savings to increase patient access to biologic medicines and lower total healthcare expenditures. Healthcare professionals and patients have been the subjects of surveys on biosimilars, but recent comprehensive quantitative data about US pharmacists’ attitudes toward and comprehension of biosimilars are scarce. The majority of US pharmacists understood the fundamental ideas behind biosimilar drugs; however, certain knowledge gaps were concentrated in the areas of interchangeability and substitution. Only slightly more than half of those surveyed said they felt confident answering patients’ inquiries about biosimilars. To bridge these gaps and boost confidence in administering biosimilars, US pharmacists need additional and targeted instructional techniques.